German Specialty Chemicals Leader Evonik Raises Rexim Pharmaceutical Amino and Keto Acid Prices by Up to 15 Percent

Evonik Industries AG announced on May 12, 2026 that it will apply a price increase of up to 15 percent on selected products within its Rexim pharmaceutical amino and keto acid portfolio. The German specialty chemicals group confirmed that the new pricing took effect immediately across all markets. Existing contracts and supply agreements signed before the announcement will be honored at their previously agreed terms until renewal.

Evonik attributes the revision to a sustained rise in energy costs, raw material expenses, and freight charges affecting its manufacturing operations. These input cost pressures have built up over recent quarters and are now being passed on to customers through higher prices for finished pharmaceutical ingredients. As of May 15, 2026, three days after the announcement, no downstream supplier has publicly commented on changes to finished-drug pricing, although industry observers expect contract renewal cycles over the coming months to reflect the new cost base.

Headquartered in Essen, Germany, Evonik is one of the world leaders in specialty chemicals. The group operates in more than 100 countries and reported sales of 14.1 billion euros and adjusted EBITDA of 1.9 billion euros in 2025, with around 31,000 employees. The Custom Solutions segment, which contains the Health Care business line and the Rexim product family, generated 5.4 billion euros in sales in 2025 with approximately 9,500 employees. The pharmaceutical amino acids and keto acids subject to the increase are produced at the Evonik Rexim site located in Ham, in the Hauts-de-France region of northern France. The facility has been operating for more than 70 years and employs around 230 people, with roughly 93 percent of its output exported to more than 60 countries.

The Rexim portfolio consists of highly purified amino acids, keto acids, and peptides intended for pharmaceutical and biopharmaceutical applications. Pharmaceutical-grade amino acids serve as building blocks for parenteral nutrition solutions administered intravenously to patients who cannot absorb nutrients through the digestive tract. They are also essential ingredients in cell culture media used to manufacture monoclonal antibodies, recombinant proteins, vaccines, and other biological drugs. During the COVID-19 vaccine ramp-up, the Ham facility ran 24 hours a day to supply amino acids required by global vaccine producers.

Keto acids, also called ketoanalogues of essential amino acids, are used in medications prescribed to patients with advanced chronic kidney disease. The best known finished product in this category is Ketosteril, marketed by Fresenius Kabi and prescribed in many countries. Patients placed on a low-protein diet take ketoanalogues to slow the progression of kidney failure, delay the start of dialysis, and prevent malnutrition while reducing the nitrogen workload on damaged kidneys. Clinical guidelines typically recommend ketoanalogues when the estimated glomerular filtration rate falls below 25 milliliters per minute.

Sectors and countries affected

The price increase will be felt primarily by pharmaceutical manufacturers, biotech companies, contract manufacturing organizations, and finished-drug producers that source amino acids and keto acids from Evonik. Buyers include large vaccine makers, infusion-solution producers, and manufacturers of kidney-disease medications. Because 93 percent of the Ham output is exported and Rexim products are registered in more than 60 countries, the impact is global. Markets with large dialysis and chronic kidney disease populations such as China, India, Brazil, the United States, Germany, and several Southeast Asian countries are expected to absorb a meaningful share of the increase, since ketoanalogue prescriptions are widely used in these regions.

Downstream effects may include higher costs for parenteral nutrition bags used in hospitals, more expensive cell culture media for biologic drug manufacturing, and pressure on the retail price of ketoanalogue tablets prescribed to chronic kidney disease patients. Health systems and insurers that reimburse these products could face incremental cost growth, although the immediate impact on patient pricing will depend on local reimbursement rules and on whether downstream manufacturers absorb part of the increase.

The announcement reflects a broader pattern in the European specialty chemicals industry, where producers have been working to offset persistent energy cost inflation linked to the restructuring of European gas supply since 2022 and elevated freight rates on global shipping lanes. Evonik did not specify which Rexim items are most affected or break down the increase by product category. Customers under fixed-price contracts retain their original terms until renewal, at which point the new pricing will apply.